Reports
Global Malaria Diagnostics Market Share, Size, Growth, Research, Forecast: By Technology: Microscopy, Rapid Diagnostic Tests, Molecular Diagnostic Tests; By Treatment Channel: Public, Private; By End User: Hospitals, Clinics, Diagnostic Centres, Others; Market Dynamics: SWOT Analysis; Regional Analysis; Supplier Landscape; 2023-2031
Global Malaria Diagnostics Market Outlook
The global malaria diagnostics market size was around USD 769.5 million in 2022, driven by the increasing prevalence of malaria. The market is likely to grow at CAGR of 5.5% during the forecast period 2023-2031 to attain a value of USD 1242.4 million by 2031.
Malaria Diagnostics Market: Introduction and Overview
Malaria refers to an intermittent and remittent fever caused by a protozoan parasite carried by female Anopheles mosquitoes that invades the red blood cells in the tropical and sub-tropical regions. Patients suffering from malaria often experience fever, chills, and flu-like symptoms. In patients infected by malaria, malaria causing parasite grows and multiplies first in the liver cells and then in the red blood cell. Malaria is usually curable, but it can become fatal if not taken care of properly. Malaria diagnostics refers to the process of identification of the parasite through blood smears under a microscope or through a rapid diagnostic test (RDT).
Based on technology, the molecular diagnostic test segment is predicted to account for a substantial market share in the malaria diagnostics market. This increase can be associated with the high accuracy of these tests in detecting different variants of malaria-causing parasites. These tests are conducted in two ways, namely the polymerase chain reaction (PCR) and quantitative or real time-PCR (qPCR). These tests help detect low parasite counts and mixed infection cases. Moreover, these tests are incredibly sensitive and highly accurate even while detecting low levels of infections. Thus, this segment is estimated to positively catalyse the market growth over the forecast period.
Based on regions, Middle East and Africa is expected to occupy a substantial share of the malaria diagnostics market during the forecast period. This growth can be attributed to the growing prevalence of malaria in the region caused by the widespread malaria vector, Anopheles gambiae, which is difficult to control. According to the WHO statistics of 2019, the African region alone was home to 94% of all malaria cases and deaths worldwide.
Moreover, with the growing geriatric population who are more susceptible to such infections, governments are increasingly investing in the healthcare sector to reduce mortality risks associated with malaria. As a result, malaria diagnostics technology is witnessing a significant demand for the early detection of the disease. These factors are expected to contribute to the industry growth significantly.
Malaria Diagnostics Market Segmentations
Market Breakup by Technology
- Microscopy
- Rapid Diagnostic Tests
- Molecular Diagnostic Tests
- Conventional PCR
- Real-Time PCR
Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by End User
- Hospitals
- Clinics
- Diagnostic Centres
- Others
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Malaria Diagnostics Market Scenario
According to the WHO statistics of 2019, an estimated 299 million malaria cases were reported in the year, while the total number of deaths caused by malaria stood at 409 thousand in 2019. Out of these, children below five years of age accounted for 67% of all malaria-related deaths worldwide. This is due to the compromised immune system of children due to malnourishment and undernutrition.
In addition, children with severe malaria infection also show severe anaemia, respiratory issues concerning metabolic acidosis, or cerebral malaria. In the malaria endemic regions, the transmission speed of malaria increases with the longer life span of mosquitoes with a human-biting tendency. For instance, in Africa, the African vector mosquito species have a longer life span and are responsible for the 90% of the world's malaria cases. In this regard, countries worldwide and international organisations are introducing initiatives to control the spread and prevent malaria risks.
For instance, the WHO’s Global Malaria Programme and Malaria Consortium's Malaria Prevention and Control Project aim to prevent, protect, and treat children in collaboration with several countries such as Burkina Faso, Cameroon, the Democratic Republic of the Congo, Ghana, Mozambique. Such developments are expected to augment the market growth in the forecast period.
Competitive Landscape of the Global Malaria Diagnostics Market
The report gives a detailed analysis of the key players in the global malaria diagnostics market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- ACCESS BIO. INC
- Abbott
- BioMérieux SA
- Ortho Clinical Diagnostics
- Thermo Fisher Scientific
- PREMIER MEDICAL CORPORATION PVT LTD.
- Siemens, Bio-Rad Laboratories, Inc.
- Hemex Health
- QuantuMDx Group Ltd.
- Meridian Bioscience Europe B.V.
- Intellectual Ventures Management LLC.
- Novartis AG
- BD
- FYODOR BIOTECHNOLOGIES
- Drucker Diagnostics
- Danaher
- Beckman Coulter, Inc.
The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model and SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Technology |
|
| Breakup by Treatment Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Malaria Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Malaria Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Malaria Epidemiology (2016-2031)
5.3 Europe Malaria Epidemiology (2016-2031)
5.4 Asia Pacific Malaria Epidemiology (2016-2031)
5.5 Latin America Malaria Epidemiology (2016-2031)
5.6 Middle East and Africa Malaria Epidemiology (2016-2031)
6 Global Malaria Diagnostics Market Overview
6.1 Global Malaria Diagnostics Market Historical Value (2016-2022)
6.2 Global Malaria Diagnostics Market Forecast Value (2023-2031)
7 Global Malaria Diagnostics Market Landscape
7.1 Global Malaria Diagnostics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Malaria Diagnostics: Product Landscape
7.2.1 Analysis by Technology
7.2.2 Analysis by End User
7.2.3 Analysis by Region
8 Malaria Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Global Malaria Diagnostics Market Dynamics
9.1 Market Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter’s Five Forces Model
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives, and Trends
9.7 Value Chain Analysis
10 Global Malaria Diagnostics Market Segmentation
10.1 Global Malaria Diagnostics Market by Technology
10.1.1 Market Overview
10.1.2 Microscopy
10.1.3 Rapid Diagnostic Tests
10.1.4 Molecular Diagnostic Tests
10.1.4.1 Conventional PCR
10.1.4.2 Real-Time PCR
10.2 Global Malaria Diagnostics Market by Treatment Channel
10.2.1 Market Overview
10.2.2 Public
10.2.3 Private
10.3 Global Malaria Diagnostics Market by End User
10.3.1 Market Overview
10.3.2 Hospitals
10.3.3 Clinics
10.3.4 Diagnostic Centres
10.3.5 Others
10.4 Global Malaria Diagnostics Market by Region
10.4.1 Market Overview
10.4.2 North America
10.4.3 Europe
10.4.4 Asia Pacific
10.4.5 Latin America
10.4.6 Middle East and Africa
11 North America Malaria Diagnostics Market
11.1 Market Share by Country
11.2 United States of America
11.3 Canada
12 Europe Malaria Diagnostics Market
12.1 Market Share by Country
12.2 United Kingdom
12.3 Germany
12.4 France
12.5 Italy
12.6 Others
13 Asia Pacific Malaria Diagnostics Market
13.1 Market Share by Country
13.2 China
13.3 Japan
13.4 India
13.5 ASEAN
13.6 Australia
13.7 Others
14 Latin America Malaria Diagnostics Market
14.1 Market Share by Country
14.2 Brazil
14.3 Argentina
14.4 Mexico
14.5 Others
15 Middle East and Africa Malaria Diagnostics Market
15.1 Market Share by Country
15.2 Saudi Arabia
15.3 United Arab Emirates
15.4 Nigeria
15.5 South Africa
15.6 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 ACCESS BIO. INC
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Abbott
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 BioMérieux SA
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Ortho Clinical Diagnostics
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Thermo Fisher Scientific
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 PREMIER MEDICAL CORPORATION PVT LTD.
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Siemens, Bio-Rad Laboratories, Inc.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Hemex Health
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 QuantuMDx Group Ltd.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Meridian Bioscience Europe B.V.
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Intellectual Ventures Management LLC.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 Novartis AG
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
22.13 BD
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisitions
22.13.5 Certifications
22.14 FYODOR BIOTECHNOLOGIES
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisitions
22.14.5 Certifications
22.15 Drucker Diagnostics
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisitions
22.15.5 Certifications
22.16 Danaher
22.16.1 Financial Analysis
22.16.2 Product Portfolio
22.16.3 Demographic Reach and Achievements
22.16.4 Mergers and Acquisitions
22.16.5 Certifications
22.17 Beckman Coulter, Inc.
22.17.1 Financial Analysis
22.17.2 Product Portfolio
22.17.3 Demographic Reach and Achievements
22.17.4 Mergers and Acquisitions
22.17.5 Certifications
23 Malaria Diagnostics Market- Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of USD 769.5 million in 2022, driven by the rising cases of malaria.
The market is anticipated to grow at a CAGR of 5.5% during the forecast period of 2023-2031 to attain a value of USD 1242.4 million by 2031.
The technologies used in the market include microscopy, rapid diagnostic tests, and molecular diagnostic tests. Molecular diagnostic tests can be further categorised into conventional PCR and real-time PCR.
The market uses public and private channels for treatment.
The end-users include hospitals, clinics, and diagnostic centres, among others.
The major regional markets include North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
The key players in the market include ACCESS BIO. INC, Abbott, BioMérieux SA, Ortho Clinical Diagnostics, Thermo Fisher Scientific, PREMIER MEDICAL CORPORATION PVT LTD., Siemens, Bio-Rad Laboratories, Inc., Hemex Health, QuantuMDx Group Ltd., Meridian Bioscience Europe B.V., Intellectual Ventures Management LLC., Novartis AG, BD, FYODOR BIOTECHNOLOGIES, Drucker Diagnostics, Danaher, and Beckman Coulter, Inc., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER